Search this website. You can use fund codes to locate specific funds

Our debt to nature

For the most part, companies have taken the immense value of nature for granted, but global ecosystems are now threatened at unprecedented levels.

The financial materiality of biodiversity loss and ecosystem degradation to many sectors can no longer be ignored as an inconvenient externality. There are also serious risks to the financial system and the global economy.

In 2021, countries are expected to agree on global goals for biodiversity and, like the Paris Agreement for climate change, the targets will be delivered by countries and companies.

The sectors that we have identified as key to halting and reversing biodiversity loss are consumer goods and retail, agrochemicals, mining and materials, oil and gas, utilities, finance and real estate.

Companies will need to urgently acknowledge their impact and dependence on nature. This will mean understanding the ways in which biodiversity and ecosystem services are relevant to their business model, be this through sourcing practices and supply chains, in the construction of new sites, or through the ways a company’s operations interact with surrounding ecosystems.

This article appears in our Q3 2020 Public Engagement Report.

Related Insights

Access all areas
If virtual shareholder meetings are conducted well, they can support investor stewardship, rather than eroding shareholder rights.
Stuck in second gear
Car manufacturers need to pick up the pace in transitioning from fossil fuels to electric vehicles, with tighter regulations on emissions looming.
Car makers under scrutiny in EOS’s Q1 Public Engagement Report
Why car makers need to accelerate their transition to electric vehicles
Public Engagement Report Q1 2021
The Public Engagement Report highlights some of the stewardship activities undertaken by EOS at Federated Hermes on behalf of its clients over Q1 2021.
How the pandemic has impacted gender inequality
Lisa Lange looks at the disproportionate impact that Covid-19 has had on women, and how this can be addressed.
Tackling post-pandemic pharmaceutical challenges
Why companies and investors need to step up to tackle pharmaceutical challenges in a post-pandemic world.

EOS Client Service and Business Development

Amy D’Eugenio,
Head of Client Service and Business Development, EOS